Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Recuiting Phase 3 ClinicalTrials.gov IDNCT07007065 SponsorAbbVie Information Provided byABBVIE INC. Study Start (Actual)2025-11-05 Primary Completion (Estimated) 2033-03 Study Completion (Estimated)2033-03 Enrollment (Estimated)561 Study TypeInterventional Last Update Posted2026-01-23 Study Overview Brief Summary…